Evidence map›Paper›PMID 38791887›Full record

ReviewCancers2024

Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy.

Olamide T Olaoba, Temitope I Adelusi, Ming Yang, Tessa Maidens, Eric T Kimchi, Kevin F Staveley-O'Carroll, Guangfu Li

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Olamide T OlaobaDepartment of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.ORCID 0000-0003-3620-4876
Temitope I AdelusiDepartment of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.
Ming YangDepartment of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.ORCID 0000-0002-4895-5864
Tessa MaidensDepartment of Surgery, University of Missouri, Columbia, MO 65212, USA.ORCID 0009-0009-7063-7430
Eric T KimchiDepartment of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.ORCID 0000-0002-5046-1142
Kevin F Staveley-O'CarrollDepartment of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.
Guangfu LiDepartment of Surgery, University of Connecticut Health Center, Farmington, CT 06030, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic cancer is the sixth leading cause of cancer-related mortality globally. As the most common form of pancreatic cancer, pancreatic ductal adenocarcinoma (PDAC) represents up to 95% of all pancreatic cancer cases, accounting for more than 300,000 deaths annually. Due to the lack of early diagnoses and the high refractory response to the currently available treatments, PDAC has a very poor prognosis, with a 5-year overall survival rate of less than 10%. Targeted therapy and immunotherapy are highly effective and have been used for the treatment of many types of cancer; however, they offer limited benefits in pancreatic cancer patients due to tumor-intrinsic and extrinsic factors that culminate in drug resistance. The identification of key factors responsible for PDAC growth and resistance to different treatments is highly valuable in developing new effective therapeutic strategies. In this review, we discuss some molecules which promote PDAC initiation and progression, and their potential as targets for PDAC treatment. We also evaluate the challenges associated with patient outcomes in clinical trials and implications for future research.

Indexed as

immunotherapyPDACtargeted therapytreatment

Identifiers

PMID38791887
PMCPMC11119842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.